TACETAEDoxorubicinCancer Research UKHepatocellular carcinoma
…ted 5 year survival of only 15% [BSG 2024, Cancer Research UK]. TACE and TAE are treatment options for intermediate BCLC stage disea…
Browse by entity family
An entity family is a category of extracted information. Choose one to browse its named entities and supporting articles.
Funders
Organisations named as supporting, sponsoring, or funding research.
5,089 articles · 9,137 mentionsInstitutionsUniversities, hospitals, research centres, networks, and public bodies.
11,350 articles · 22,378 mentionsDrugsNamed medicines, compounds, vaccines, and pharmacological agents.
10,506 articles · 58,393 mentionsDiseasesNamed diseases, disorders, syndromes, injuries, and health conditions.
23,712 articles · 125,551 mentionsTreatmentsClinical therapies and care approaches used to manage a condition.
7,227 articles · 16,644 mentionsInterventionsProgrammes, procedures, policies, and other actions being evaluated.
4,132 articles · 9,994 mentionsClinical instrumentsNamed questionnaires, scales, scores, indices, and other clinical outcome assessments.
945 articles · 1,957 mentions29,499matching articles
244,054matching entity mentions
30popular entities listed
0%of mentions human-reviewed
Popular entities in these results
Choose an entity to see the articles in which it was identified.
EMBASE784PUBMED717COVID-19645Cancer605SLE570Diabetes552NHS522WEB OF SCIENCE499Hypertension418SCOPUS417HIV406Systemic Lupus Erythematosus390Heart Failure364Asthma349Stroke336COPD331WHO330Colorectal Cancer327Cardiovascular Disease317Type 2 Diabetes316Chronic Obstructive Pulmonary Disease313Joanna Briggs Institute306MEDLINE306Atrial Fibrillation283Cochrane Library275Breast Cancer271Hepatocellular Carcinoma253SSc251Inflammatory Bowel Disease250Obesity246
Matching articles
29,499 articles · page 48 of 2459liver cancerAFPPBCAIHSwansea Bay University Health Boardliver diseaseHCCNational Institute for Health and Care ExcellencePSCcurative treatment+2 more
…ancer related deaths in the UK. The most common form of primary liver cancer is hepatocellular carcinoma (HCC), which makes up 85% of all li…
avacopanantineutrophil cytoplasmic antibody-associated vasculitisazathioprinecyclophosphamideprednisonemycophenolate mofetil
…ere achieved by 37/59 (62.7%) and 33/59 (55.9%) patients in the avacopan group and 34/57 (59.6%) and 30/57 (52.6%) in the prednisone tap…
cSDHMiami Clinical and Translational Science InstituteNational Center for Advancing Translational ScienceseMMAMount SinaiTRUFILL n-BCANational Institute on Minority Health and Health DisparitiesNIHNational Institute of Health
…rtery (eMMA) with a liquid embolic is an emerging treatment for cSDH. The prospective, global, multicentre, open-label MEMBRANE stud…
contralateral breast cancerbreast cancerradiotherapycontralateral breast cancerschemotherapy
…the general population, and 5.6% (5.5% to 5.6%) had developed a contralateral breast cancer, 3.1% (3.0% to 3.2%) more than expected. The absolute excess ri…
Azathioprineinflammatory bowel diseaseIBD
…e the range and 37% (10) were within range (table 2).Conclusion Azathioprine metabolite monitoring is more common in adult IBD management, a…
ticagrelorezetimibemultivessel coronary artery diseaselow-dose rivaroxabanSGLT2 inhibitorsPCSK9 inhibitorsCerebrovascular diseaseGLP1 agonistsNICElong-term dual antithrombotic therapy+3 more
… long-term dual antithrombotic therapy (low-dose rivaroxaban or ticagrelor). This study compared cardiovascular outcomes of patients seen …
rheumatoid arthritisepilepsyrelapsing-remitting multiple sclerosisheart failureFDAchronic or recurrent depressionMedtronic
…ion, chronic or recurrent depression as adjunctive therapy, and rheumatoid arthritis, all commercially available as FDA approved systems. It is also…
CRCoxaliplatincolorectal cancer5-FU5-fluorouracil
…oned media (CM) derived from Ri were applied to chemo-resistant CRC cell lines (HCT8/FU, HCT8/L, HCT116/FU, HCT116/L). Cell viabili…
HCCliver transplantationcirrhosisdiabetes
…2026-ABS-0285 Figure 2). In women without cirrhosis, the annual HCC incidence was 0.01% for HBsAg loss ≤50 years, 0.06% for 51 - 60…
E2 disease8B3 disease2B2 disease2E3 disease8E1 disease7IBDB1 disease51UC ulcerative colitisCrohn’s disease
…SD) = 51.57 years old (11.36 years old)% E1 disease7 (30. 43%)% E2 disease8 (34.78%)% E3 disease8 (34.78%)Mean duration of disease (standar…